Irritable Bowel and Bacterial Overgrowth Syndromes: a Bacterial Link Hypothesis of Functional Disease
https://doi.org/10.22416/1382-4376-2021-31-1-54-63
Abstract
Aim. Assessment of the irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth syndrome (SIBO) interlinkage.
Key points. SIBO may represent a "peripheral" mechanism of IBS, aside to nonspecific inflammation, increased epithelial permeability and local immune system activation. In various assays, the SIBO rate in IBS patients was 4-46% vs. 0-13% in an intact cohort. A limited diagnosability of SIBO obscures the SIBO-IBS causal interplay. Impaired motility in IBS may predispose to the SIBO development. Proinflammatory cytokines and mediators in SIBO, in turn, provoke visceral hypersensitivity and intense motility, the key IBS factors. Both conditions relate to qualitative and quantitative changes in microbiota, which warrants the application of probiotic Lactobacillus and Bifidobacterium strains.
Conclusion. Further research into the SIBO-IBS interface is required for developing optimal probiotic-based therapies.
Keywords
small intestinal bacterial overgrowth,
irritable bowel syndrome,
gut microbiota,
probiotics,
Lactobacillus,
Bifidobacterium
Supporting agencies: The publication was supported by Valenta Pharmaceuticals.
About the Authors
K. V. Ivashkin
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Konstantin V. Ivashkin — Cand. Sci. (Med.), Ass. Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1.
V. R. Grechishnikova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vasilisa R. Grechishnikova — Clinical Resident, Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1.
M. S. Reshetova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Maria S. Reshetova — Clinical Resident, Chair of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1.
V. T. Ivashkin
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vladimir T. Ivashkin — Member of the Russian Academy of Sciences, Prof., Dr. Sci. (Med.), Head of the Chair of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine; Director, Vasilenko Clinic of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1, bld. 1.
References
1. Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002; 123(6):2108—31. DOI: 10.1053/gast.2002.37095
2. Li B., Liang L., Deng H., Guo J., Shu H., Zhang L. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Front Pharmacol. 2020;11:332. DOI: 10.3389/fphar.2020.00332
3. Laskaratos F.M., Goodkin O., Thoua N.M., Murray C.D. Irritable bowel syndrome. Med (United Kingdom). 2015; 43(5):266-70. DOI: 10.1016/j.mpmed.2015.02.010
4. Ivashkin V.T., Shelygin Yu.A., Baranskaya Ye.K., Belousova Ye.A., Beniashvili A.G., Vasiliev S.V., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(5):76-93 (In Russ.). DOl: 10.22416/1382-4376-2017-27-5-76-93
5. Lovell R.M., Ford A.C. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7):712—21. DOI: 10.1016/j.cgh.2012.02.029
6. Buono J.L., Carson R.T., Flores N.M. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):1—8. DOI: 10.1186/s12955-017-0611-2
7. Tack J., Stranghellini V., Mearin F., Yiannakou Y., Layer P., Coffin B., Tack J., et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2009;19(1):69. DOI: 10.1186/s12876-019-0985-1
8. Maev I.V., Kucheryaviy Yu.A., Andreev D.N., Ivashkina N.Yu. Small bowel bacterial overgrowth syndrome: clinical relevance, criteria of therapeutic managemant. Infectious Deseases: News Opinions Training. 2016;3:118-25 (In Russ.).
9. Ghoshal U.C., Shukla R., Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy. Gut Liver. 2017;11(2):196-208. DOI: 10.5009/gnl16126
10. Barbara G., Feinle—Bisset Ch., Ghoshal U., Santos J., Vanner S., Vergnolle N., et al. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016;150(6):1305-18. DOI: 10.1053/j.gastro.2016.02.028
11. Ghoshal U.C., Gwee K.A. Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: The missing link. Nat Rev Gastroenterol Hepatol. 2017;14(7):435-41. DOI: 10.1038/nrgastro.2017.37
12. Ivashkin V.T., Maev I.V., Tsar'kov P.V., Korolev M.P., Andreev D.N., Baranskaya Ye.K. Diagnosis and Treatment of Peptic ulcer in Adults (Clinical guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Rus J Gastroenterol Hepatol Coloproctol. 2020;30(1):49-70 (In Russ.). DOI: 10.22416/1382-4376-2020-30-1-49-70
13. Alp M.H., Court J.H., Grant A., Grant K., Australia S. Personality pattern and emotional stress in the genesis of gastric ulcer.1970;11:773-7.
14. Jones M.P. The role of psychosocial factors in peptic ulcer disease: Beyond Helicobacter pylori and NSAIDs. J Psychosom Res. 2006; 60(4):407-12. DOI: 10.1016/j.jpsychores.2005.08.009
15. Drossman D.A. Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262-79. DOI:10.1053/j.gastro.2016.02.032
16. Pimentel M., Chow E.J., Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503-6. DOI: 10.1016/S0002-9270(00)02161-4
17. Posserud I., Stotzer P.O., B^rnsson E.S., Abrahamsson H., Sim-rcn M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802-8. DOI: 10.1136/gut.2006.108712
18. Kerckhoffs A.P.M., Visser M.R., Samson M., Van Der Rest M.E., De Vogel J., Harmsen W., et al. Critical evaluation of diagnosing bacterial overgrowth in the proximal small intestine. J Clin Gastroenterol. 2008;42(10):1095-102. DOI: 10.1097/MCG.0b013e31818474d7
19. Pyleris E., Tzivras D., Barbatzas C., Giamarellos-Bourboulis E.J., Koussoulas V., Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: Relationship with irritable bowel syndrome. Dig Dis Sci. 2012:57(5):1321-9. DOI: 10.1007/s10620-012-2033-7
20. Ghoshal U.C., Srivastava D., Ghoshal U., Misra A. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol. 2014;26(7):753-60. DOI: 10.1097/MEG.0000000000000122
21. Erdogan A., Rao S.S.C., Gulley D., Jacobs C., Lee Y.Y., Badger C. Small intestinal bacterial overgrowth: Duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015;27(4):481-9. DOI: 10.1111/nmo.12516
22. Nucera G., Gabrielli M., Lupascu A., Lauritano E.C., Santoliquido A., Cremonini F., et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;21(11):1391-5. DOI: 10.1111/j.1365-2036.2005.02493.x
23. Scarpellini E., Giorgio V., Gabrielli M., Lauritano E.C., Pantanella A., Fundaro C., et al. Prevalence of Small Intestinal Bacterial Overgrowth in Children with Irritable Bowel Syndrome: A Case-Control Study. J Pediatr. 2009;155(3):416-20. DOI: 10.1016/j.jpeds.2009.03.033
24. Park J.S., Yu J.H., Lim H.C., Kim J.H., Yoon Y.H., Park H.J., et al. Usefulness of lactulose breath test for the prediction of small intestinal bacterial overgrowth in irritable bowel syndrome Korean J Gastroenterol. 2010;56(4):242-8. DOI: 10.4166/kjg.2010.56.4.242
25. Rana S.V., Sharma S., Kaur J., Sinha S.K., Singh K. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Digestion. 2012; 85(3): 243—7. DOI: 10.1159/000336174
26. Zhao J., Zheng X., Chu H., Zhao J., Cong Y., Fried M., et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic orocecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neuro-gastroenterol Motil. 2014;26(6):794-802. DOI: 10.1111/nmo.12331
27. Lupascu A., Gabrielli M., Lauritano E.C., Scarpellini E., Santoliquido A., Cammarota G., et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: A prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(11 — 12):1157-60. DOI: 10.1111/j.1365-2036.2005.02690.x
28. Lombardo L., Foti M., Ruggia O., Chiecchio A. Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy. Clin Gastroenterol Hepatol. 2010;8(6):504-8. DOI: 10.1016/j.cgh.2009.12.022
29. Sachdeva S., Rawat A.K., Reddy R.S., Puri A.S. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: Frequency and predictors. J Gastroenterol Hepatol. 2011;26(3):135-8. DOI: 10.1111/j.1440-1746.2011.06654.x
30. Moraru I.G., Portincasa P., Moraru A.G., Diculescu M., Dumitrascu D.L. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study. Rom J Intern Med. 2013;51(3-4):143-7.
31. Abbasi M.H., Zahedi M., Moghadam S.D., Shafieipour S., Abbasi M.H. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran. Middle East J Dig Dis. 2015;7(1):36-40.
32. Ford A.C., Spiegel B.M.R., Talley N.J., Moayyedi P. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279-86. DOI: 10.1016/j.cgh.2009.06.031
33. Spiegel B.M.R., Chey W.D., Chang L. Bacterial overgrowth and irritable bowel syndrome: Unifying hypothesis or a spurious consequence of proton pump inhibitors? American Journal of Gastroenterology. 2008;103(12):2972-6. DOI: 10.1111/j.1572-0241.2008.01992.x
34. Chen B., Kim J.J.W., Zhang Y., Du L., Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018;53(7):807-18. DOI: 10.1007/s00535-018-1476-9
35. Shah A., Talley N.J., Jones M., Kendall B.J., Kolos-ki N., Walker M.M., et al. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Am J Gastroenterol. 2020;115(2):190-201. DOI: 10.14309/ajg.0000000000000504
36. Spiller R., Garsed K. Infection, inflammation, and the irritable bowel syndrome. Digestive and Liver Disease, 2009;41(12):844-9. DOI:10.1016/j.dld.2009.07.007
37. Bures J., Cyrany J., Kohoutova D., Forstl M., Rejchrt S., Kvetina J., et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24);2978-90. DOI: 10.3748/wjg.v16.i24.2978
38. Kunkel D., Basseri R.J., Makhani M.D., Chong K., Chang C., Pimentel M. Methane on breath testing is associated with constipation: A systematic review and meta-analysis. Dig Dis and Sci. 2011;56(6):1612-8. DOI: 10.1007/s10620-011-1590-5
39. Pimentel M. Evaluating a bacterial hypothesis in ibs using a modification of kochs postulates: Part 1. Am J Gastroenterol. 2010;105(4):718-21. DOI: 10.1038/ajg.2009.678
40. Khoshini R., Dai S.C., Lezcano S., Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008;53(6):1443-54. DOI: 10.1007/s10620-007-0065-1
41. Pimentel M. Breath testing for small intestinal bacterial overgrowth: Should we bother? American Journal of Gastroenterology. 2016;111(3):307-8. DOI: 10.1038/ajg.2016.30
42. Shukla R., Ghoshal U., Dhole T.N., Ghoshal U.C. Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis. Dig Dis Sci. 2015;60(10):2953-62. DOI: 10.1007/s10620-015-3607-y
43. Malinen E., Rinttila T., Kajander K., Matto, Kassinen A., Krogius L., et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100(2):373-82. DOI: 10.1111/j.1572-0241.2005.40312.x
44. Choi C.H., Chang S.K. Role of small intestinal bacterial overgrowth in functional gastrointestinal disorders. J Neurogastroenterol Motil. 2016;22(1):3-5. DOI: 10.5056/jnm15196
45. Ghoshal U.C., Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype. World J Gastroenterol. 2014;20(10):2482-91. DOI: 10.3748/wjg.v20.i10.2482
46. DiBaise J.K., Young R.J., Vanderhoof J.A. Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol. 2006;4(1):11-20. DOI: 10.1016/j.cgh.2005.10.020
47. Bures J., Cyrany J., Kohoutova D., Forstl M., Rejchrt S., Kvetina J., et al. Small intestinal bacterial overgrowth syndrome. World J. Gastroenterol. 2010;16(24):2978-90. DOI: 10.3748/wjg.v16.i24.2978
48. Schmulson M., Bielsa M.V., Carmona-Sanchez R., Hernandez A., Lopez-Colombo A., Lopez Vidal Y., et al. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: An evidence-based review. Revista de Gastroenterologia de Mexico. 2014;79(2):96-134. DOI: 10.1016/j.rgmx.2014.01.004
49. Guilarte M., Santos J., De Torres I., Alonso C., Vicario M., Ramos L., et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56(2):203-9. DOI: 10.1136/gut.2006.100594
50. Hasler W.L. Traditional Thoughts on the Pathophysiology of Irritable Bowel Syndrome. Gastroenterology Clinics of North America. 2011;40(1):21-43. DOI: 10.1016/j.gtc.2010.12.004
51. Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrel G.S., Santini D., et al. Activated Mast Cells in Proximity to Colonic Nerves Correlate with Abdominal Pain in Irritable Bowel Syndrome. Gastroenterology. 2004;126(3):693-702. DOI: 10.1053/j.gastro.2003.11.055
52. Srivastava D., Ghoshal U., Mittal R.D., Ghoshal U.C. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil. 2014;26(10):1408-16. DOI: 10.1111/nmo.12399
53. Rana S.V., Sharma S., Sinha S.K., Parsad K.K., Malik A., Singh K. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoeapredominant irritable bowel syndrome patients. Trop Gastroenterol. 2012;33(4):251-6. DOI: 10.7869/tg.2012.66
54. Banik G.D., De A., Som S., Jana S., Daschakraborty S.B., Chaudhuri S., et al. Hydrogen sulphide in exhaled breath: A potential biomarker for small intestinal bacterial overgrowth in IBS. J Breath Res. 2016;10(2):26010. DOI: 10.1088/1752-7155/10/2/026010
55. Medani M., Collins D., Docherty N.G., Baird A.W., O'Connell P.R., Winter D.C. Emerging role of hydrogen sulfide in colonic physiology and pathophysiology. Inflamm Bowel Dis. 2011;17(7):1620-5. DOI: 10.1002/ibd.21528
56. Weinstock L.B., Klutke C.G., Lin H.C. Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. Dig Dis Sci. 2008;53(5):1246-51. DOI: 10.1007/s10620-007-0022-z
57. Bouhnik Y., Alain S., Attar A., Flourie B., Raskine L., Sanson-Le Pors M.J., Rambaud J.C. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. 1999;94(5):1327-31. DOI: 10.1111/j.1572-0241.1999.01016.x
58. Jeffery I.B., O’Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M.M., et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997-1006. DOI: 10.1136/gutjnl-2011-301501
59. Kim G., Deepinder F., Morales W., Hwang L., Weitsman S., Chang Ch., et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci. 2012;57(12):3213-8. DOI: 10.1007/s10620-012-2197-1
60. Salem A.E., Singh R., Ayoub Y.K., Khairy A.M., Mullin G.E. The gut microbiome and irritable bowel syndrome: State of art review. Arab J Gastroenterol. 2018;19(3):136-41. DOI: 10.1016/j.ajg.2018.02.008
61. Salonen A., De Vos W.M., Palva A. Gastrointestinal microbiota in irritable bowel syndrome: Present state and perspectives. Microbiology. 2010; 156(11): 3205-3215. DOI: 10.1099/mic.0.043257-0
62. Rajilic-Stojanovic M., Jonkers D.M., Salonen A., Hanevik K., Raes J., Jalanka J., et al. Intestinal microbiota and diet in IBS: Causes, consequences, or epiphenomena? American Journal of Gastroenterology. 2015;110(2):278-87. DOI: 10.1038/ajg.2014.427
63. Kerckhoffs A.P.M., Samson M., van der Rest M.E., Knol J., Ben-Amor K., Akkermans L.M.A. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol. 2009;15(23):2887-92. DOI: 10.3748/wjg.15.2887
64. Yuan F., Ni H., Asche C.V., Kim M., Walayat S., Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191-7. DOI: 10.1080/03007995.2017.1292230
65. Sundin J., Aziz I., Nordlander S., Polster A., Hu Y.O.O., Hugerth L.W., et al. Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome. Sci Rep. 2020;10(1):1-13. DOI: 10.1038/s41598-020-57468-y
66. Pimentel M., Saad R.J., Long M.D., Rao S.S.C. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165-78. DOI: 10.14309/ajg.0000000000000501
67. Ivashkin V.T., Maev I.V., Okhlobystin A.V., Kucheryavyy Yu.A., Trukhmanov A.S., et al. Guidelines of the Russian gastroenterological association on diagnostics and treatment of a chronic pancreatitis. Rus J Gastroenterol Hepatol Coloproctol. 2014;4:70-97 (In Russ.).
68. Leventogiannis K., Gkolfakis P., Spithakis G., Tsatali A., Pistiki A., Sioulas A., et al. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. Probiotics Antimicrob Proteins. 2019;11(2):627-34. DOI: 10.1007/s12602-018-9401-3
69. Ivashkin V.T., Maev I.V., Abdulganieva D.I., Alexeenko S.A., Ivashkina N.Yu., Korochanskaya N.V., et al. Practical clinical guidelines of the NSOIM and Russian gastroenterological assocoation on probiotics use for treatment and prevention of gastroenteroogical diseases. Rus J Gastroenterol Hepatol Coloproctol. 2020;30(2):76-89 (In Russ.) DOI: 10.22416/1382-4376-2020-30-2-76-89
70. Guarino M.P.L., Altomare A., Stasi E., Marignani M., Severi C., Alloni R., et al. Effect of acute mucosal exposure to Lactobacillus rhamnosus GG on human colonic smooth muscle cells. J Clin Gastroenterol. 2008;42(3, no. September):16-8. DOI: 10.1097/mcg.0b013e31817e1cac
71. Guglielmetti S., Mora D., Gschwender M., Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life — A double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(10):1123-32. DOI: 10.1111/j.1365-2036.2011.04633.x
72. Bonfrate L., Di Palo D.M., Celano G., Albert A., Vitellio P., De Angelis M., et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest. 2020;50(3):1-10. DOI: 10.1111/eci.13201
73. Sisson G., Ayis S., Sherwood R.A., Bjarnason I., Valley Hospital D. Randomised clinical trial: a liquid multistrain probiotic vs. placebo in the irritable bowel syn-drome-a 12 week double-blind study. Aliment Pharmacol Ther. 2014; 40: 51-62. DOI: 10.1111/apt.12787
74. Dale H.F., Rasmussen S.H., Asiller O.O., Lied G.A. Probiotics in irritable bowel syndrome: An up-to-date systematic review. Nutrients. 2019;11(9): 2048. DOI: 10.3390/nu11092048
75. Ivashkin V.T., Drapkina O.M., Sheptulin A.A., Shifrin O.S., Poluektova Ye.A., Kuchumova S.Yu., et al. Comparative assessment of Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus and Saccharomyces boulardii efficacy at diarrheal variant of irritable bowel syndrome. Rus J Gastroenterol Hepatol Coloproctol. 2015;25(2):10-21 (In Russ.).
76. Ivashkin V., Drapkina O., Poluektova Ye., Kuchumova S., Sheptulin A., Shifrin O. The Effect of a Multistrain Probiotic on the Symptoms and Small Intestinal Bacterial Overgrowth in Constipation-predominant Irritable Bowel Syndrome: A Randomized, Simple-blind, Placebo-controlled Trial. American Journal of Clinical Medicine Research. 2015;3(2):18-23. DOI: 10.12691/ajcmr-3-2-1
77. Jeffery I.B., O’Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M.M., et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997-1006. DOI: 10.1136/gutjnl-2011-301501
78. Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tima S., et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1792-801. DOI: 10.1053/j.gastro.2011.07.043
79. Simren M., Barbara G., Flint H.J., Spiegel B., Spiller R.C., Vanner S., et al. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut. 2013;62(1):159-76. DOI: 10.1136/gutjnl-2012-302167
80. Krogius-Kurikka L., Lyra A., Malinen E., Aarnikunnas J., Tuimala J., Paulin L., et al. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009. DOI: 10.1186/1471-230X-9-95
81. Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(5). DOI: 10.1111/j.1365-2982.2009.01427.x
Review
For citations:
Ivashkin K.V., Grechishnikova V.R., Reshetova M.S., Ivashkin V.T. Irritable Bowel and Bacterial Overgrowth Syndromes: a Bacterial Link Hypothesis of Functional Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(1):54-63. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-1-54-63
Views:
2325
Email this article 
